Yellow Fever Vaccine Trial
Funder: NIH through University of Minnesota
Start Date: Projected end date is November 2022
End Date:
Summary
The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccination. Under regulatory review.
Update
REC and UNCST have approved. NDA approval is still pending. Recruitment has not started yet. To start after approval and training.
CoVPN 3008(UBUNTU)
Funder: Sponsor-South African Medical Research Council (SAMRC). DAIDS study.
Start Date:
End Date: Projected end date is in 2023.
Summary
Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
Update
Undergoing final regulatory processes. Started trainings.Hope to start screening participants in November 2021.
Vat 00008 study
Funder: Sponsor-Sanofi Pasteur Inc.
Start Date: Projected to start participant recruitment in early 2022.
End Date:
Summary
Study of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and Older.
Update
Undergoing final regulatory processes.
OTAC study
Funder: Sponsor-University of minnesota. Funded by NIAID.
Start Date: projected to start in 2022
End Date:
Summary
Outpatient Treatment with AntiCoronavirus Immunoglobulin INSIGHT Protocol Number: 012.
Update
Undergoing regulatory processes.
TWN-Wantai Study
Funder: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd
Start Date: Currently projected to start in 2022
End Date:
Summary
A Global, Multi-center, Randomized, Double-blind, Placebo controlled Phase III Clinical Trial to Evaluate the
Protective Efficacy and Safety of Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1) in Adults Aged 18 Years and Older
Update
Undergoing site registration processes.
INNOVATE study.
Funder: INOVIO Pharmacueticals
Start Date: Currently projected to start in 2022
End Date:
Summary
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine against COVID 19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARSCoV-2 Exposure.
Update
Undergoing site registration processes.
A5372
Funder: NIH/DAIDS Sponsor: AIDS Clinical Trials Group
Start Date: Projected Cancelled, JCRC will not participate in this protocol
End Date:
Summary
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals.
A5379
Funder: NIH/DAIDS Sponsor: AIDS Clinical Trials Group
Start Date: Projected to start in November 2021 when pending approvals are got.
End Date:
Summary
B-ENHANCEMENT OF HBV VACCINATION IN PERSONS LIVING WITH HIV (BEe-HIVe): Evaluation of HEPLISAV-B
Update
All local approvals were received, Pending DPRS approval. (responding to the comments by DPRS) re-submitted to JCRC.Have not yet started recruitment of participants.
Peripheral Arterial Disease (PAD)
Funder: Funder: NIH Sponsor: case western reserve university
Start Date: Next phase of trainings was projected to start on 16th and 23rd October 2021 when the sponsor comes. This was done.
End Date:
Summary
Ankle-Brachial index screening for peripheral artery disease in Uganda. Building a training model and exploring the feasibility and acceptability of implementation strategies.
Update
Received IRB/REC renewal approval. and UNCST approval. Does not require NDA approval. Finished first phase and will soon resume 2nd stage.
ACTIV2/A5401
Funder: NIH/DAIDS Sponsor: AIDS Clinical Trials Group
Start Date: Projected to start in November 2021
End Date:
Summary
Master protocol accessing therapeutics in COVID-19 in non-hospitalized patients.
Update
Version 7.0 was submitted to the JCRC REC on 29/Sep/2021
Convalescent Plasma Project
Funder: Government of Uganda through PRESIDE and MOSTI.
Start Date: Project did not takeoff due to delayed funding.
End Date:
Summary
Collection of convalescent plasma from individuals who have recovered from COVID-19 infection for possible use in critically ill patients with COVID19 as a therapeutic
Update
Project waiting for funds.
Stem cell research project.
Funder: Global gene Therapy initiative.
Start Date: Projected to start after setting up an infrastructure.
End Date:
Summary
Stem cell research in the management of diseases like Sickle cell.
Update
Project still in initial stages. Preparing to start gene therapy.
One Health
Funder: WHO / TDR
Start Date: projected to start in 2022
End Date: Projected to end in Q1 of 2024
Summary
Approach to identify Local Drivers of Antmicrobial Drug Resistance in peri-urban Kampala, Uganda.
Update
Original submission to REC was done, comments were given and currently responding to these for re-submission. Have not yet started implementing the protocol
UNITE4TB project
Funder: Funder: European Union
Start Date: To start after getting approvals.
End Date:
Summary
First round review was completed.
Update
Initial stage.(site assessment and registration.)
Breather Plus
Funder: EDCTP
Start Date: Currently projected to start in early 2022
End Date: Projected to end in Q1 of 2024
Summary
A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle therapy (five days on, two days off) dolutegravirbased antiretroviral therapy (ART) compared to daily dolutegravirbased ART in virologically suppressed HIV-infected adolescents aged 12-<20 years of age in sub-Saharan Africa.
LATA
Funder: JANSSEN / MRCCTU
Start Date: Currently projected to start in Jan 2022
End Date: Projected to end in Q2 of 2024
Summary
A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of 8-weekly dual long-acting injectable antiretroviral therapy (ART) compared to daily dolutegravir-based triple ART in virologically suppressed HIVinfected adolescents aged 12-<20 years in sub-Saharan Africa
D3 (PENTA) 21
Funder: ViiV / PENTA/ MRC-CTU
Start Date: Projected to start recruitment in Dec 2021
End Date:
Summary
A randomised non-inferiority trial with nested PK to assess DTG/3TC fixed dose formulations for the maintenance of virological suppression in children with HIV infection aged 2 to <15 years old
Another PAINT Follow on study (TMC278HTX2002)
Funder: Janssen Research and Development
Start Date: Currently projected to start in early 2022
End Date:
Summary
A Phase 2, Open-label, Singlearm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed
CARMA-GLOBAL
Funder: PENTA
Start Date:
End Date:
Summary
A cross-sectional study of children with perinatally-acquired HIV infection who started ART at a young age, four or more years ago, and who are currently in care on ART. The aim is to describe the size and profile of the persisting viral reservoir and associated immunological parameters after several years of ART after initiation of treatment at a young age.
UNIVERSAL
Funder: EDCTP
Start Date:
End Date:
Summary
Pharmacokinetic and safety studies of new antiretroviral formulations: expediting UNIVERSAL first and second line regimens for all children living in Africa.